Drug Trial Radar · NCT05611671
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
280
Actual
Start
Nov 21, 2022
Primary completion
Nov 28, 2024
Study completion Sep 21, 2026
Sponsor
- Lead sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Industry
- Sponsor type
- Industry
- First posted
- Nov 10, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
Conditions
- Inflammatory Bowel Diseases
- Colitis, Ulcerative
Interventions
MORF-057Drug
MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.
PlaceboDrug
Matching placebo (identical appearance to MORF-057) administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants in Clinical Remission as Determined Using the Modified Mayo Clinic Score (mMCS)Time frame: Week 12
Locations
102 sites in 21 countries. Site status is shown where the registry gives one.
Arizona Digestive Health - Sun City
Sun City, Arizona
Gastro Care Institute
Lancaster, California
TLC Clinical Research Inc.
Los Angeles, California
Innova Clinical Trials
Coral Gables, Florida
Eminat, LLC - Miramar
Miramar, Florida
Robert Wood Johnson University Medical School
New Brunswick, New Jersey
Great Lakes Gastroenterology
Mentor, Ohio
The University of Texas Health Science Center at Houston
Houston, Texas
Blacktown Hospital
Blacktown, Australia
Concord Repatriation General Hospital
Concord, Australia
Royal Brisbane and Women's Hospital
Herston, Australia
Fiona Stanley Hospital
Murdoch, Australia
Mater Adult Hospital Brisbane
South Brisbane, Australia
Order Hospital Linz Ltd. - Hospital of Sisters of Mercy
Linz, Austria
Salzburg Regional Hospital
Salzburg, Austria
Medical University of Vienna
Vienna, Austria
Medical Center "Rusemed" EOOD
Rousse, Bulgaria
University Multiprofile Hospital for Active Treatment "ACIBADEM City Clinic"
Sofia, Bulgaria
Acibadem City Clinic Multiprofile Hospital for Active Treatment Tokuda
Sofia, Bulgaria
Second Multiprofile Hospital for Active Treatment - Sofia
Sofia, Bulgaria
PreventaMed, s.r.o.
Olomouc, Czechia
Clinoxus s.r.o., Outpatient Clinic Budejovicka
Prague, Czechia
LV Venter OU
Pärnu, Estonia
OU Innomedica
Tallinn, Estonia
East Tallinn Central Hospital
Tallinn, Estonia
West Tallinn Central Hospital
Tallinn, Estonia
University of Tartu
Tartu, Estonia
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet
Nice, France
Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC
Tbilisi, Georgia
Curatio, Jsc
Tbilisi, Georgia
JSC Infectious Diseases, AIDS and Clinical Immunology Research Center
Tbilisi, Georgia
LTD Aversi Clinic
Tbilisi, Georgia
Medical Center "CITO" Ltd.
Tbilisi, Georgia
LTD The First Medical Center
Tbilisi, Georgia
Charite - University Hospital Berlin
Berlin, Germany
Krankenhaus Waldfriede
Berlin, Germany
University Hospital Schleswig-Holstein
Kiel, Germany
University Hospital Ulm
Ulm, Germany
Semmelweis Medical University
Budapest, Hungary
Semmelweis University, Department of Internal Medicine and Haematology, Division of Internal Medicine and Gastroenterology
Budapest, Hungary
Showing 40 of 102 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.